Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839097 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
A Phase 1 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01839097 is a Phase 1 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 23 participants.
The verdict
NCT01839097, a Phase 1 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
Interventions
- DRUG Belinostat
- DRUG CHOP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839097
The ClinicalTrials.gov registry entry for NCT01839097 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Belinostat is the first listed.
NCT01839097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839097 about?
NCT01839097 is a clinical study titled "Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)". The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
What is the current status of trial NCT01839097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-05. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01839097?
The interventions under investigation include: Belinostat (DRUG), CHOP (DRUG).
Who is sponsoring clinical trial NCT01839097?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.